Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 1

Status

Recruiting 2Unknown 1Enrolling by invitation 1

Sponsor Class

OTHER 2OTHER_GOV 1INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

NET 4Endocrine 4Genitourinary 1Gastrointestinal 1

Conditions

Neuroendocrine Tumors 4Differentiated Thyroid Cancer 2Adenoma, Islet Cell 2Tuberous Sclerosis 1Thyroid Cancer, Papillary 1Pituitary Neoplasms 1Neoplasms 1Multiple Endocrine Neoplasia Type 1 1Insulinoma 1Hyperinsulinism 1Growth Hormone-Secreting Pituitary Adenoma 1Gastroenteropancreatic Neuroendocrine Tumors 1Congenital Hyperinsulinism 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Carcinoid Tumor 1Advanced Extrapulmonary Neuroendocrine Cancer 1Adenocarcinoma, Follicular 1Acromegaly 1

Interventions

lutetium Lu 177 dotatate 40Everolimus 35Magnetic Resonance Spectroscopy 15lanreotide 14gallium Ga 68 dotatate 13Temozolomide 13Octreotide 12Nivolumab 12pembrolizumab 11Capecitabine 11surufatinib 10177Lu-octreotide, DOTA(0)-Tyr(3)- 10cabozantinib 9Positron Emission Tomography Computed Tomography 93-Iodobenzylguanidine 9Sunitinib 8Specimen Handling 7Carboplatin 7telotristat ethyl 6pasireotide 6amino-acid, glucose, and electrolyte solution 6Somatostatin 6Lutetium-177 690Y-octreotide, DOTA-Tyr(3)- 6lenvatinib 5Ipilimumab 5Ga(III)-DOTATOC 5Fluorodeoxyglucose F18 5Etoposide 5Cisplatin 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Neuroendocrine Tumors × Injections × Endocrine × Clear all
NCT07369505 2026-01-27

Sapu003 in Advanced mTOR-sensitive Solid Tumors

SAPU NANO (US) LLC

Phase 1 Recruiting
27 enrolled
EndocrineGastrointestinalGenitourinaryNET

Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Tuberous Sclerosis, Neuroendocrine Tumors

NCT07121478 2025-10-01

Patients With High-grade Pancreatic Neuroendocrine Tumors

National Cancer Center, Korea

Phase 2 Enrolling by invitation
46 enrolled
EndocrineNET

Adenoma, Islet Cell, Neuroendocrine Tumors

NCT04837885 2025-07-23

LUTARTERIAL

University Hospital, Bordeaux

Phase 2 Recruiting
23 enrolled
EndocrineNET

Neoplasms, Neuroendocrine Tumors

NCT02455596 2016-01-05

Recombinant Anti-tumor and Anti-virus Protein for Injection to Treat Advanced Neuroendocrine Tumors

The Affiliated Hospital of the Chinese Academy of Military Medical Sciences

Phase 2 Unknown
20 enrolled
EndocrineNET

Carcinoid Tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡